Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while ...

Findings reveal that a structured home rehabilitation program boosts lung function and quality of life in bronchiectasis ...

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially ...

Paediatric-onset bronchiectasis leads to more severe disease than adult-onset, highlighting need for early, tailored care.

More than half of severe COVID-19 survivors show fibrotic-like lung abnormalities even 3 years after infection, especially ...

Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin ...

Background Antimicrobial resistance (AMR) is a growing global health crisis and is particularly relevant to people living ...

Treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis are under review.

Insmed Incorporated (NASDAQ:INSM) is one of the stocks on Jim Cramer’s radar. A caller noted that Cramer has not been quick ...

The two companies will scale production for a novel recombinant version of alpha-1 antitrypsin targeting lung diseases.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...